All Posts By

Smartkarma Daily Briefs

Nov 17
0

Daily Brief Energy/Materials: Yankuang Energy Group, Chemours Co/The, Cleveland-Cliffs Inc , Energy Transfer LP, Permian Resources , Western Midstream Partners LP and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • FXI Rebalance Preview: One Change in December as Shorts Spike
  • The Chemours Company: Its’ Strategic Portfolio Overhaul Maximizing Returns in High-Growth Markets! – Major Drivers
  • Cleveland-Cliffs Inc.: Can The Stelco Acquisition Be A Game Changer? – Major Drivers
  • Energy Transfer LP: Can Its Expansion of Infrastructure & Capacity Be A Potential Game Changer? – Major Drivers
  • Permian Resources: These Are The 4 Biggest Challenges In Its Path In 2025 & Beyond! – Major Drivers
  • Western Midstream Partners: Capital Allocation & Leverage Management As A Vital Factor Driving Growth! – Major Drivers

FXI Rebalance Preview: One Change in December as Shorts Spike

By Brian Freitas

The Chemours Company: Its’ Strategic Portfolio Overhaul Maximizing Returns in High-Growth Markets! – Major Drivers

By Baptista Research

  • The Chemours Company’s third-quarter 2024 results present a mixed picture, reflecting both commendable strategic implementation and ongoing market challenges.
  • The quarter witnessed a 1% increase in consolidated net sales to approximately $1.5 billion, driven by a 5% rise in volume, though partially offset by a 3% decline in pricing and a slight currency headwind.
  • This reflects the company’s effective operational execution and successful navigation through previous disruptions, evidenced by year-over-year volume growth across all business segments.

Cleveland-Cliffs Inc.: Can The Stelco Acquisition Be A Game Changer? – Major Drivers

By Baptista Research

  • Cleveland-Cliffs presented its third-quarter 2024 results during a challenging period of weaker steel demand and pricing, largely attributed to reduced automotive production and high interest rates affecting consumer decisions.
  • The company’s acquisition of Stelco, a Canadian steelmaker, was a notable development during this period, promising operational agility and cost efficiency.Cleveland-Cliffs reported a quarterly adjusted EBITDA of $124 million on 3.8 million tons of shipments.
  • This was a decline from previous performance levels, which the company attributed to reduced activity in the automotive industry.

Energy Transfer LP: Can Its Expansion of Infrastructure & Capacity Be A Potential Game Changer? – Major Drivers

By Baptista Research

  • Energy Transfer’s third quarter of 2024 results reveal several positive developments alongside some challenges, reflecting a complex operating environment.
  • Financially, Energy Transfer generated an adjusted EBITDA of $3.96 billion compared to $3.54 billion in the same quarter of the previous year, indicating growth driven by record volumes across its pipelines and strong performance in crude and NGL exports.
  • Despite the improved EBITDA, distributable cash flow attributable to partners remained flat at $1.99 billion year-over-year.

Permian Resources: These Are The 4 Biggest Challenges In Its Path In 2025 & Beyond! – Major Drivers

By Baptista Research

  • Permian Resources delivered a robust performance in the third quarter of 2024, characterized by significant production gains and operational efficiencies.
  • The company increased its full-year oil production guidance for the third time this year, highlighting a rise in daily production by 11,000 barrels over the initial forecast set in February.
  • A substantial part of this increase is attributed to the outperformance of its core operations, coupled with effective execution in mergers and acquisitions, notably the successful integration of the Barilla Draw acquisition.

Western Midstream Partners: Capital Allocation & Leverage Management As A Vital Factor Driving Growth! – Major Drivers

By Baptista Research

  • Western Midstream Partners’ third quarter of 2024 report presents a mixed bag of operational achievements and financial challenges.
  • Under the new leadership of Oscar Brown, the company continues to pursue its strategic goals while navigating through a complex market environment.
  • On the operational front, Western Midstream Partners reported a commendable quarter characterized by strong customer service and maintaining over 98% operability despite increased plant turnaround activities.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 17
0

Daily Brief Industrials: S.F. Holding, GXO Logistics, Howmet Aerospace , Trimas Corp and more

By | Daily Briefs, Industrials

In today’s briefing:

  • SF Holding Pre-IPO: Three Important Issues for Long-Term Investors to Consider
  • GXO Logistics Inc.: Expanding E-Fulfillment Capabilities to Set New Standards! – Major Drivers
  • Howmet Aerospace Inc.: Capitalizing on Explosive Commercial Aerospace Growth for 2025! – Major Drivers
  • TriMas Corporation: Strategic Divestitures & Acquisitions As A Key Growth Catalyst! – Major Drivers

SF Holding Pre-IPO: Three Important Issues for Long-Term Investors to Consider

By Daniel Hellberg

  • SF Holding’s domestic parcel volumes have grown slower than overall market volumes recently; is this strategic, or simply a loss of share?
  • SF Holding is not closely aligned with any of the large online retail platforms in China; ultimately, is this independence an advantage or a disadvantage?
  • When will SF Holdings’ varied international operations — and there are a few of them — begin to pull their own weight, in terms of profitability and growth?

GXO Logistics Inc.: Expanding E-Fulfillment Capabilities to Set New Standards! – Major Drivers

By Baptista Research

  • GXO Logistics’ latest earnings for the third quarter of 2024 painted a mixed yet informative picture of its financial performance and strategic positioning.
  • The company reported record revenues of $3.2 billion, marking a substantial year-over-year increase of 28%.
  • This robust top-line growth is partially attributed to an organic revenue growth of 3%, which has shown a sequential upward trend throughout the fiscal year.

Howmet Aerospace Inc.: Capitalizing on Explosive Commercial Aerospace Growth for 2025! – Major Drivers

By Baptista Research

  • Howmet Aerospace’s third quarter 2024 results demonstrate significant performance gains amidst a complex operating environment.
  • The company’s revenue growth was substantial at 11% year-over-year, with commercial aerospace driving much of this improvement with a 17% increase in revenue.
  • The engine products and fasteners segments excelled, supported by robust structures performance.

TriMas Corporation: Strategic Divestitures & Acquisitions As A Key Growth Catalyst! – Major Drivers

By Baptista Research

  • TriMas Corporation reported its third-quarter 2024 results, highlighting both positive trends and challenges across its business segments.
  • The company operates three key segments: TriMas Packaging, TriMas Aerospace, and Specialty Products, which together offer a diversified portfolio designed to leverage opportunities across different markets.In the TriMas Packaging segment, the company achieved a notable 12% increase in net sales compared to the same quarter last year.
  • This growth was primarily driven by high demand in the beauty, personal care, and home care markets, where organic sales increased over 20%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 17
0

Daily Brief Financials: China International Capital Corporation and more

By | Daily Briefs, Financials

In today’s briefing:

  • A/H Premium Tracker (To 15 Nov 2024): AH Premia Rise Sharply; Hs Shellacked Vs As In Most Sectors

A/H Premium Tracker (To 15 Nov 2024): AH Premia Rise Sharply; Hs Shellacked Vs As In Most Sectors

By Travis Lundy

  • Huge volumes continue to be traded on the mainland share markets. SOUTHBOUND volumes bounced, and net buying was both large and broad-based.
  • Stocks in HK and mainland markets fell heavily with HK’s main indices down 6-7% and China’s blue chip indices down 3.3-3.6% (CSI 500 – 4.8%). 
  • Within H/A Pairs, after outperforming the HK/mainland spread for weeks, spreads got shellacked. Worst week in a long time (-3.7%), perhaps on the back of “disappointing” lack of stimulus measures.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 17
0

Daily Brief Health Care: Jiangxi Boya Bio Pharmaceutical, Asahi Intecc, Glaukos Corp, Jazz Pharmaceuticals, Gilead Sciences, Mckesson Corp, Novo Nordisk A/S, Royalty Pharma and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China Healthcare Weekly (Nov.17) – TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross
  • 2024 High Conviction Update: Asahi Intecc (7747 JP)- Medical Division Drives Q1 Result
  • Glaukos Corporation: Advancement of iDose TR & Market Penetration As A Pivotal Growth Lever! – Major Drivers
  • Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers
  • How Gilead Sciences’ HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth! – Major Drivers
  • McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers
  • Novo Nordisk: Global Adoption & Expansion of GLP-1 Therapeutics Driving Our Bullishness! – Major Drivers
  • Royalty Pharma Plc: Revolutionizing Biopharma with Synthetic Royalty Funding Innovations! – Major Drivers

China Healthcare Weekly (Nov.17) – TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross

By Xinyao (Criss) Wang

  • The new round of national TCM decoction pieces VBP has started. We think the overall price reduction would be relatively mild, and the impact on related TCM enterprises is limited.
  • The NHSA will vigorously promote the expansion of TCM VBP, which is another challenge for TCM injections. But the impact on exclusive TCM varieties and innovative TCM injections is smaller.
  • CR Boya has completed the acquisition of 100% equity of Green Cross and has included it in the scope of consolidated financial statements starting from November. Future M&As will continue.

2024 High Conviction Update: Asahi Intecc (7747 JP)- Medical Division Drives Q1 Result

By Tina Banerjee

  • Asahi Intecc (7747 JP) recorded 9% YoY revenue growth to ¥31B in Q1FY25. Revenue growth is attributable to the continued strong trajectory of medical division, which reported 10% YoY growth.
  • Strong rebound in China is key highlight for medical division performance. Revenue from China increased by a whopping 36% YoY and 44% QoQ to a record high of ¥9.3B.
  • Despite a better-than-expected Q1FY25, the company maintains full-year FY25 guidance, due to external factors such as currency movements as well as uncertainties in trends for net sales, productivity, and expenditure.

Glaukos Corporation: Advancement of iDose TR & Market Penetration As A Pivotal Growth Lever! – Major Drivers

By Baptista Research

  • Glaukos Corporation’s third quarter 2024 financial results highlighted a period of notable growth driven by strategic product developments and an expanding market presence.
  • The company achieved record consolidated net sales of $96.7 million, representing a 24% increase from the previous year.
  • This performance prompted Glaukos to revise its full-year 2024 net sales guidance upwards to $377 million to $379 million, reflecting optimism about continued growth.

Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers

By Baptista Research

  • Jazz Pharmaceuticals recently reported its third quarter 2024 financial results, reflecting a period of noteworthy commercial growth and strategic progression, particularly in its neuroscience and oncology business units.
  • The company recorded a total revenue exceeding $1.05 billion, a 9% increase compared to the same quarter in 2023.
  • This growth was primarily fueled by the continued strong performance of Xywav and Epidiolex in the neuroscience segment, with both products achieving record quarterly sales and double-digit year-over-year growth.

How Gilead Sciences’ HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth! – Major Drivers

By Baptista Research

  • Gilead Sciences, Inc. reported a strong financial performance for the third quarter of 2024, showcasing robust growth across its main therapeutic areas, including HIV, oncology, and liver disease.
  • This growth has allowed Gilead to increase its full-year guidance for key financial metrics such as revenue, operating income, and earnings per share, underscoring its effective commercial and operational execution.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers

By Baptista Research

  • McKesson Corporation’s second quarter fiscal 2025 results present a multidimensional view of the company’s current financial standing and future prospects.
  • With reported record revenues of $93.7 billion, McKesson demonstrated a robust 21% year-over-year increase, driven significantly by the U.S. Pharmaceutical segment.
  • This sector alone witnessed a 23% revenue boost, underscored by the onboarding of a new strategic partner and broadened specialty product distribution.

Novo Nordisk: Global Adoption & Expansion of GLP-1 Therapeutics Driving Our Bullishness! – Major Drivers

By Baptista Research

  • Novo Nordisk recently presented its third-quarter financial results, showcasing significant growth and strategic developments within the company.
  • The key highlights from the call indicate robust expansion across various segments, particularly driven by the strong performance of its diabetes and obesity treatments, including notable products like Ozempic and Wegovy.
  • The company reported an impressive 24% increase in sales alongside a 22% rise in operating profit for the first nine months of the fiscal year.

Royalty Pharma Plc: Revolutionizing Biopharma with Synthetic Royalty Funding Innovations! – Major Drivers

By Baptista Research

  • Royalty Pharma, a leading investor in biopharmaceutical royalties, recently reported its third-quarter 2024 results.
  • The company highlighted strong business momentum, driven by its diverse portfolio of more than 35 commercial products.
  • Financially, Royalty Pharma achieved a 15% growth in both Portfolio Receipts and Royalty Receipts.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 17
0

Daily Brief Industrials: S.F. Holding, GXO Logistics, Howmet Aerospace , Trimas Corp and more

By | Daily Briefs, Industrials

In today’s briefing:

  • SF Holding Pre-IPO: Three Important Issues for Long-Term Investors to Consider
  • GXO Logistics Inc.: Expanding E-Fulfillment Capabilities to Set New Standards! – Major Drivers
  • Howmet Aerospace Inc.: Capitalizing on Explosive Commercial Aerospace Growth for 2025! – Major Drivers
  • TriMas Corporation: Strategic Divestitures & Acquisitions As A Key Growth Catalyst! – Major Drivers

SF Holding Pre-IPO: Three Important Issues for Long-Term Investors to Consider

By Daniel Hellberg

  • SF Holding’s domestic parcel volumes have grown slower than overall market volumes recently; is this strategic, or simply a loss of share?
  • SF Holding is not closely aligned with any of the large online retail platforms in China; ultimately, is this independence an advantage or a disadvantage?
  • When will SF Holdings’ varied international operations — and there are a few of them — begin to pull their own weight, in terms of profitability and growth?

GXO Logistics Inc.: Expanding E-Fulfillment Capabilities to Set New Standards! – Major Drivers

By Baptista Research

  • GXO Logistics’ latest earnings for the third quarter of 2024 painted a mixed yet informative picture of its financial performance and strategic positioning.
  • The company reported record revenues of $3.2 billion, marking a substantial year-over-year increase of 28%.
  • This robust top-line growth is partially attributed to an organic revenue growth of 3%, which has shown a sequential upward trend throughout the fiscal year.

Howmet Aerospace Inc.: Capitalizing on Explosive Commercial Aerospace Growth for 2025! – Major Drivers

By Baptista Research

  • Howmet Aerospace’s third quarter 2024 results demonstrate significant performance gains amidst a complex operating environment.
  • The company’s revenue growth was substantial at 11% year-over-year, with commercial aerospace driving much of this improvement with a 17% increase in revenue.
  • The engine products and fasteners segments excelled, supported by robust structures performance.

TriMas Corporation: Strategic Divestitures & Acquisitions As A Key Growth Catalyst! – Major Drivers

By Baptista Research

  • TriMas Corporation reported its third-quarter 2024 results, highlighting both positive trends and challenges across its business segments.
  • The company operates three key segments: TriMas Packaging, TriMas Aerospace, and Specialty Products, which together offer a diversified portfolio designed to leverage opportunities across different markets.In the TriMas Packaging segment, the company achieved a notable 12% increase in net sales compared to the same quarter last year.
  • This growth was primarily driven by high demand in the beauty, personal care, and home care markets, where organic sales increased over 20%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 17
0

Daily Brief Consumer: Alibaba Group Holding , Seven & I Holdings, Toyota Motor Corp Spon Adr, Johnson Controls, MercadoLibre , Performance Food Group Co, Wynn Resorts, Cvs Health Corp, Duolingo and more

By | Consumer, Daily Briefs

In today’s briefing:

  • HK Connect SOUTHBOUND Flows (To 15 Nov 2024); Tech Bought, High-Div SOEs Sold or Ignored, Again
  • Weekly Deals Digest (17 Nov) – Seven & I, Fuji Soft, Nishimoto, Macromill, CPMC, KEPCO, SF Holding
  • Last Week in Event SPACE: Seven & I, PA Gooddoctor, Nec Networks, Genscript/Legend, ASM PT, Hanwha
  • Toyota Motor Corporation: Their Adaptation & Strategy in the Chinese Market Driving Our ‘Buy’ Rating! – Major Drivers
  • Johnson Controls: These Are The 7 Biggest Factors Impacting Its Performance In 2025 &Beyond! – Major Drivers
  • MercadoLibre Inc.: How Are They Successfully Tackling Supply Chain and Fulfillment Challenges? – Major Drivers
  • Performance Food Group Company: Will Its Enhanced Focus on Digital Ordering Tools Pay Off? – Major Drivers
  • How Wynn Resorts is Revolutionizing Global Gaming with Strategic Expansion Projects! – Major Drivers
  • CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers
  • Duolingo Inc.: Leveraging AI & User Engagement For A Competitive Edge! – Major Drivers

HK Connect SOUTHBOUND Flows (To 15 Nov 2024); Tech Bought, High-Div SOEs Sold or Ignored, Again

By Travis Lundy

  • SOUTHBOUND gross trading activity still high. Net buying very strong. 7 names traded more than US$1bn. Last week I said tech would continue to be bought. It was.
  • The trend continues to net sales of ETFs and high div SOEs. Net buying is very, very broad-based. Tracker Fund of Hong Kong (2800 HK) is batted around like crazy.
  • I expect HK-listed tech to continue getting bought. Alibaba, Tencent, Xiaomi, etc are safe havens against Trump tariffs as they don’t compete in the US.

Weekly Deals Digest (17 Nov) – Seven & I, Fuji Soft, Nishimoto, Macromill, CPMC, KEPCO, SF Holding

By Arun George

Last Week in Event SPACE: Seven & I, PA Gooddoctor, Nec Networks, Genscript/Legend, ASM PT, Hanwha

By David Blennerhassett

Toyota Motor Corporation: Their Adaptation & Strategy in the Chinese Market Driving Our ‘Buy’ Rating! – Major Drivers

By Baptista Research

  • Toyota Motor Corporation has announced its fiscal year 2025 second-quarter financial results.
  • The company achieved an operating income of JPY 2.4642 trillion for the first half of the fiscal year, which was maintained close to the previous year despite some setbacks in production and increases in expenses.
  • While sales revenue touched JPY 23.2824 trillion, the net income of JPY 1.9071 trillion saw a significant decrease from the prior year, primarily due to exchange rate fluctuations which caused valuation losses in foreign currency assets.

Johnson Controls: These Are The 7 Biggest Factors Impacting Its Performance In 2025 &Beyond! – Major Drivers

By Baptista Research

  • The Johnson Controls International plc (JCI) fourth-quarter fiscal 2024 earnings revealed significant insights into the company’s performance and strategic direction.
  • Here is an analysis considering both the positive and negative aspects.
  • The positive highlights include strong financial performance and strategic advancements.

MercadoLibre Inc.: How Are They Successfully Tackling Supply Chain and Fulfillment Challenges? – Major Drivers

By Baptista Research

  • MercadoLibre reported robust financial results for the third quarter of 2024, showcasing strong performance across its e-commerce and fintech sectors in Latin America.
  • The company’s gross merchandise volume (GMV) saw significant growth, with Brazil witnessing a 34% increase year-on-year and Mexico a 27% rise.
  • Moreover, the company made substantial gains in market share in these key countries.

Performance Food Group Company: Will Its Enhanced Focus on Digital Ordering Tools Pay Off? – Major Drivers

By Baptista Research

  • Performance Food Group’s (PFG) recent earnings conference call revealed several key developments and financial results for the first quarter of the fiscal year 2025.
  • The call focused on strategic acquisitions, financial performance, and market conditions affecting the company.In terms of acquisitions, PFG completed two significant deals: purchasing Jose Santiago, a leading foodservice distributor in Puerto Rico, and Cheney Brothers, a major player in the Southeast U.S. foodservice market.
  • The integration of Jose Santiago has been smooth, with the company already positively contributing to PFG’s results.

How Wynn Resorts is Revolutionizing Global Gaming with Strategic Expansion Projects! – Major Drivers

By Baptista Research

  • In the recent results, Wynn Resorts reported mixed performance across its key markets during the third quarter of 2024.
  • In Las Vegas, the company faced challenging comparisons from the previous year but managed to increase normalized revenue by 1%.
  • The gaming segment, however, saw a dip in table drop, which the management attributed to high-end consumer segment volatility rather than any structural issues.

CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers

By Baptista Research

  • CVS Health’s recent third-quarter 2024 earnings report presents a multifaceted view of the company’s performance and strategic direction.
  • The company’s revenue reached approximately $95.4 billion, marking a 6% increase from the previous year.
  • However, the adjusted earnings per share (EPS) of $1.09 indicate challenges, particularly within the Health Care Benefits (HCB) segment.

Duolingo Inc.: Leveraging AI & User Engagement For A Competitive Edge! – Major Drivers

By Baptista Research

  • Duolingo, a prominent player in the online language learning space, has reported its financial results for the third quarter of 2024, outlining both strengths and areas to watch.
  • The company demonstrated robust growth in key metrics, including a 54% year-over-year increase in daily active users (DAUs), with its Family Plan onboarding 21% of its subscriber base.
  • This impressive user growth, particularly after a high growth rate in previous years, suggests that Duolingo continues to successfully engage its expanding user base.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 16
0

Daily Brief Quantitative Analysis: Hong Kong Buybacks Weekly (Nov 15th): AIA and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • Hong Kong Buybacks Weekly (Nov 15th): AIA, Cosco Shipping, Sinopec

Hong Kong Buybacks Weekly (Nov 15th): AIA, Cosco Shipping, Sinopec

By Ke Yan, CFA, FRM

  • We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Nov 15th based on HKEx daily reports.
  • In the past 7 days, the top 3 companies that repurchased the most shares from the market were AIA (1299 HK), Cosco Shipping (1919 HK), Sinopec (386 HK).
  • In the past 30 days, the top 3 companies that repurchased the most shares from the market were AIA (1299 HK), Cosco Shipping (1919 HK), Swire Pacific (19 HK).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 16
0

Daily Brief Thematic (Sector/Industry): Themes of India: A Deeper Look at Rural India’s Economic Rise and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Themes of India: A Deeper Look at Rural India’s Economic Rise
  • Japan Weekly | Mixed Market but Plenty Going On
  • China’s Ageing Population Challenge: Lessons from US Healthcare Spending
  • Shroom Shmooz Psychedelics: Trends to Watch Going into 2025
  • 2025 Outlook: Focus Is on Top Line – November 13, 2024
  • The US Elections’ Impact on 2025 Outlook – November 13, 2024
  • AUCTUS ON FRIDAY – 15/11/2024
  • Five Biopharma Trends for 2025 – November 13, 2024

Themes of India: A Deeper Look at Rural India’s Economic Rise

By Nimish Maheshwari

  • The rural economy plays a crucial role in driving India’s growth, contributing just under half of the total GDP and providing livelihoods for about two-thirds of the population. 
  • The trend which is emerging is rural economy growing faster than urban, hence we deep dive into the what and why of this trend
  • The urban slowdown has caused concern for India Inc’s earning growth.

Japan Weekly | Mixed Market but Plenty Going On

By Mark Chadwick

  • The Japanese market ended the week on a mixed note, with the Nikkei 225 Index down 2.2%
  • Stocks moves were largely dictated by earnings. Furukawa’s full year upward revision was a standout, while THK surprised the market with a punchy buyback
  • Watchlist: ASICS continues to perform well and will upgrade its mid-term outlook this week. Nexon and Appier could be worth a look after recent stock price declines

China’s Ageing Population Challenge: Lessons from US Healthcare Spending

By Avien Pillay

  • China’s over-65 demographic is projected to grow by 50% in the next decade, driving increased demand for healthcare services, eldercare, and technology.
  • The healthcare sector in China presents a significant investment opportunity as the country addresses the needs of its ageing population.
  • Insights from the US, where healthcare spending is closely tied to an ageing population, can inform strategies for growth in China’s healthcare market, offering potential for long-term returns.

Shroom Shmooz Psychedelics: Trends to Watch Going into 2025

By Water Tower Research

  • For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA for its MDMA-AT candidate for PTSD.
  • The FDA’s decision flew in the face of the anticipatory excitement following the NDA submission and award of breakthrough therapy designation earlier in the year following impressive results from Lykos’ two- part Phase 3 trial.
  • However, as disappointing as it is, particularly for the many millions of PTSD sufferers and Lykos, which subsequently reduced its workforce by 75%, in the grand scheme of things, this is only a temporary setback.

2025 Outlook: Focus Is on Top Line – November 13, 2024

By Water Tower Research

  • While our potential universe includes a broad range of branded consumer companies across the market capitalization, one corner of that universe that we have done a lot of work on over the years involves those companies utilizing a direct selling business model, which deploys a sales force of independent contractors to get their products in the hands of consumers.
  • The top trend we are monitoring for 2025 is the impact that the burgeoning market for GLP-1 drugs has on the weight loss stocks.
  • Two pure-play weight- loss names we monitor, MED and WW, have already been severely affected by the disruption caused by the GLP-1 drugs and have been on the defensive in recent years.

The US Elections’ Impact on 2025 Outlook – November 13, 2024

By Water Tower Research

  • Elections have consequences. The November 2024 elections in the US have ushered in not just a change in political landscape for the country and the makeup of the federal government but are likely to result in material changes to government policies and priorities for 2025 and beyond.
  • These include international trade, the federal regulatory environment, and tax policies that can affect consumer sentiment, company strategies when it comes to capital deployment, and end market dynamics.
  • While specifics could emerge in the coming months, we expect modest inflationary pressures from expected tariffs on imported goods to be largely offset by more constructive energy policies, tax incentives, and a reduced federal regulatory burden, along with a reduced federal government role in economic decision-making to lead to an improvement in economic growth in 2025.

AUCTUS ON FRIDAY – 15/11/2024

By Auctus Advisors

  • Arrow Exploration (AXL LN/CN)C; Target price of £0.70 per share: 1.9 mbbl/d at latest CN well.
  • Water disposal infrastructure operational.
  • High net cash – The fifth horizontal well at Carrizales Norte (CNB HZ-6) is producing 1.9 mbbl/d of oil (0.95 mbbl/d net to Arrow) with a water cut of 31%.

Five Biopharma Trends for 2025 – November 13, 2024

By Water Tower Research

  • Biopharma will navigate the uncertainty that comes with the Trump presidency and his alliance with a populist healthcare agenda, but the less regulation-minded Republicans should be good for the group, reducing scrutiny on M&A and drug prices.
  • We highlight five biopharma themes and trends heading into 2025.
  • Less FTC scrutiny should drive biopharma M&A. Biopharma M&A has meaningfully slowed since mid-year, adding eight deals at >$50MM after the LLY-MORF acquisition in early July, which brings the YTD total to 34 and no longer on pace to exceed 2022 (43 deals) or 2023 (38 deals).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 16
0

Daily Brief ESG: Side Effects of Matching Numbers to Raise the Percentage of Female Board Members and more

By | Daily Briefs, ESG

In today’s briefing:

  • Side Effects of Matching Numbers to Raise the Percentage of Female Board Members

Side Effects of Matching Numbers to Raise the Percentage of Female Board Members

By Aki Matsumoto

  • With external female board member resources under pressure, it will be extremely difficult to raise the percentage of female board members steadily at this rate.
  • The trump card for this is matching numbers. Increasingly, female board members with no management background or outside talent are being recruited to female managerial positions.
  • It is expected that fewer companies will move to Company with US type 3 Statutory Committees in order to avoid increasing the number of statutory executive officers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Nov 16
0

Daily Brief Credit: Lucror Analytics – Morning Views Asia and more

By | Credit, Daily Briefs

In today’s briefing:

  • Lucror Analytics – Morning Views Asia

Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • Fed Chairman Jerome Powell yesterday said that there is no need for the US central bank to rush rate cuts.
  • He said: “The economy is not sending any signals that we need to be in a hurry to lower rates,” adding that “the strength we are currently seeing in the economy gives us the ability to approach our decisions carefully”.
  • Following Mr Powell’s comments, traders reduced their expectations for an interest-rate cut in December to 60% from 80% earlier. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free